Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
testalize-me-0jE8ynV4mis-unsplash
Oryzon Genomics (BME: ORY) further strengthens vafidemstat’s intellectual property profile
Published by Arron Aatkar, PhD

Oryzon Genomics has received new ‘decision to grant’ communications from the Canadian Intellectual Property Office and the Israel Patent Office. This is for its patents ‘Methods of treating behavior alterations’ for lead CNS candidate, vafidemstat, as a potential treatment to address aggression and social withdrawal. Once granted, these patents will remain in force until at least 2038 in Canada and Israel, excluding any potential patent term extensions (which have the potential to add additional years of protection).

Oryzon is currently preparing for a Phase III programme, which will evaluate vafidemstat for the treatment of aggression in patients with borderline personality disorder.

Latest

Healthcare | Comment

Herantis Pharma (HEL: HRTIS) – a step closer to Phase II

Investment Companies | Comment

The Biotech Growth Trust (BIOG) reported encouraging H126 results

TMT | Comment

Nanoco (LSE:NANO) settles LG litigation for $5m

Healthcare | Comment

Mendus (OMX: IMMU) announces c SEK50m directed share issue